Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1335419rdf:typepubmed:Citationlld:pubmed
pubmed-article:1335419lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:1335419lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1335419lifeskim:mentionsumls-concept:C0242402lld:lifeskim
pubmed-article:1335419lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:1335419lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:1335419lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:1335419pubmed:issue3lld:pubmed
pubmed-article:1335419pubmed:dateCreated1993-2-1lld:pubmed
pubmed-article:1335419pubmed:abstractTextMorphine, naltrexone and naloxone inhibited the binding of [3H]clonidine to the alpha 2-adrenoceptors in human platelet membranes, provided that Mg2+ was present in the medium. In the presence of 5'-guanylyl imidophosphate (Gpp(NH)p) or in the absence of Mg2+ morphine did not modify the binding of [3H]clonidine. Neither [D-Ala2,N-MePhe4,Gly5-ol]enkephalin (DAGO), nor [D-Pen2,D-Pen5]enkephalin (DPDPE), nor dynorphin-(1-17) affected the [3H]clonidine binding. The presence of 1 mM naloxone did not alter the affinity of either [3H]clonidine or [3H]yohimbine, but reduced the number of binding sites of [3H]clonidine, having no effect on [3H]yohimbine. Naloxone inhibited the binding of adrenaline to high- but not low-affinity sites. It is concluded that morphine and semisynthetic antagonist derivatives interact with alpha 2-adrenoceptors only in the high-affinity state.lld:pubmed
pubmed-article:1335419pubmed:languageenglld:pubmed
pubmed-article:1335419pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1335419pubmed:citationSubsetIMlld:pubmed
pubmed-article:1335419pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1335419pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1335419pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1335419pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1335419pubmed:statusMEDLINElld:pubmed
pubmed-article:1335419pubmed:monthNovlld:pubmed
pubmed-article:1335419pubmed:issn0014-2999lld:pubmed
pubmed-article:1335419pubmed:authorpubmed-author:OruiTTlld:pubmed
pubmed-article:1335419pubmed:authorpubmed-author:BallestaJ JJJlld:pubmed
pubmed-article:1335419pubmed:issnTypePrintlld:pubmed
pubmed-article:1335419pubmed:day2lld:pubmed
pubmed-article:1335419pubmed:volume227lld:pubmed
pubmed-article:1335419pubmed:ownerNLMlld:pubmed
pubmed-article:1335419pubmed:authorsCompleteYlld:pubmed
pubmed-article:1335419pubmed:pagination349-51lld:pubmed
pubmed-article:1335419pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1335419pubmed:meshHeadingpubmed-meshheading:1335419-...lld:pubmed
pubmed-article:1335419pubmed:meshHeadingpubmed-meshheading:1335419-...lld:pubmed
pubmed-article:1335419pubmed:meshHeadingpubmed-meshheading:1335419-...lld:pubmed
pubmed-article:1335419pubmed:meshHeadingpubmed-meshheading:1335419-...lld:pubmed
pubmed-article:1335419pubmed:meshHeadingpubmed-meshheading:1335419-...lld:pubmed
pubmed-article:1335419pubmed:meshHeadingpubmed-meshheading:1335419-...lld:pubmed
pubmed-article:1335419pubmed:meshHeadingpubmed-meshheading:1335419-...lld:pubmed
pubmed-article:1335419pubmed:meshHeadingpubmed-meshheading:1335419-...lld:pubmed
pubmed-article:1335419pubmed:meshHeadingpubmed-meshheading:1335419-...lld:pubmed
pubmed-article:1335419pubmed:year1992lld:pubmed
pubmed-article:1335419pubmed:articleTitleInteraction of opioid drugs with human platelet alpha 2-adrenoceptors.lld:pubmed
pubmed-article:1335419pubmed:affiliationDepartamento de Neuroquimica, Facultad de Medicina, Universidad de Alicante, Spain.lld:pubmed
pubmed-article:1335419pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1335419pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1335419lld:pubmed